DOCSLIB.ORG

Taqpath COVID-19 Combo

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Taqpath COVID-19 Combo TaqPath™ COVID-19 Combo Kit and ™ TaqPath COVID‑19 Combo Kit Advanced* INSTRUCTIONS FOR USE Multiplex real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS‑CoV‑2 *TaqPath™ COVID-19 Combo Kit Advanced reagent volumes have been optimized for workflows that use 14.0 μL or 17.5 μL of purified sample RNA Catalog Numbers A47813 and A47814 Publication Number MAN0019181 Revision J.0 For In Vitro Diagnostic Use. For Emergency Use Authorization Only | Rx Only Lif e Technologies Corporation | 6055 Sunol Blv d | Pleasanton, Calif ornia 94566 USA For descriptions of sy mbols on product labels or product documents, go to thermofisher.com/symbols-definition. The customer is responsible for compliance with regulatory requirements that pertain to their procedures and uses of the instrument. The information in this guide is subject to change w ithout notice. DISCLAIMER: TO THE EXTENT ALLOWED BY LAW, THERMO FISHER SCIENTIFIC INC. AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR A RISING FROM THIS DOCUMENT, INCLUDING Y OUR USE OF IT. Rev ision history : Pub. No. MAN0019181 Rev ision Date Description J.0 22 February 2021 Prov ided new options f or RT-PCR plates. H.01 10 December 2020 Internal document control update only , with no changes to Instructions f or Use rev . H.0 released on DCO1199965 and posted to the thermof isher.com website. Update to align the 20 Nov 2020 FDA-released Instructions f or Use with remov al of the licensing statement cov ering Limited Use Label Licenses on page 2. H.0 10 Nov ember 2020 • The instructions f or using the TaqPath™ COVID-19 Combo Kit Adv anced were updated to indicate that the kit is now compatible with all instruments. • The compatible COVID‑19 Interpretiv e Sof tware v ersions were updated to v 1.5 and 2.5, which include amplif ication curv es. • Instructions were added on what to do in the ev ent of bead carry ov er f rom RNA extraction. • The licensing statement cov ering Limited Use Label Licenses was remov ed f rom page 2. G.0 9 October 2020 • Guidance and protocols were added f or samples collected using the Ev erly well™ COVID-19 Test Home Collection Kit, including use of the new TaqMan™ SARS-CoV-2 RNase P Assay Kit. • Inf ormation and protocols were added f or the TaqPath™ COVID-19 Combo Kit Adv anced (Cat. No. A47813), which supports preparation of RT-PCR reactions f rom 17.5 µL and 14.0 µL of purif ied sample RNA. • “Intended Use” on page 9 and Chapter 12, “Conditions of authorization f or labs” were updated with inf ormation f or the Ev erly well™ COVID-19 Test Home Collection Kit and the TaqPath™ COVID-19 Combo Kit Adv anced. • COVID‑19 Interpretiv e Sof tware v 1.4 and v .2.4 were added to support use of the RNase P assay, and instructions f or obtaining the sof tware were updated. • Minor corrections were made to the kit conf iguration inf ormation f or the TaqPath™ COVID-19 Combo Kit. • General laboratory recommendations were added (see page 18). • The name of the Wash Buf f er was changed to Wash Solution in the RNA extraction procedures. A note was added that the Wash Solution can dev elop particulates but this does not af f ect perf ormance. • “Interpretation of the results” on page 106 was updated to include results f or the RNase P assay and guidance on reporting results to the appropriate public health authorities. • Minor updates were made to the Intended Use. F.0 15 July 2020 • Added Applied Biosystems™ COVID‑19 Interpretiv e Sof tware v 1.3 and Applied Biosystems™ COVID‑19 Interpretiv e Sof tware v 2.3. • Remov ed Applied Biosystems™ COVID‑19 Interpretiv e Sof tware v 1.2, Applied Biosystems™ COVID‑19 Interpretiv e Sof tware v 2.0, and Applied Biosystems™ COVID‑19 Interpretiv e Sof tware v 2.2. • Added Ct cutof f information (Appendix B, “Ct cutof f v alues f or assay targets”). • Remov ed instructions to mix by pipetting up and down 10 times when preparing RT-PCR plates. Added instructions to v ortex the plates to ensure proper mixing. • Updated centrif uge and sealing instructions when preparing the RT-PCR plates. • Updated instructions to create a unique name f or each well in the phy sical plate, not just the wells with a patient sample. Rev ision Date Description F.0 15 July 2020 • Updated reactiv ity (inclusivity) (page 115) and the warnings and precautions (page 16). (continued) • Specif ied that retesting must be perf ormed by re-extracting the original sample and repeating the RT-PCR (“Interpretation of the results” on page 106). E.0 12 May 2020 Added the f ollowing products as an alternativ e to the KingFisher™ 96 KF microplate f or the tip comb plate: • Tip Comb Presenting Plate f or KF 96 • Nunc™ MicroWell™ 96‑Well Microplate, barcoded • Nunc™ MicroWell™ 96‑Well Microplate, Flat Bottom • Nunc™ F96 MicroWell™ Black Poly sty rene Plate • KingFisher™ Deep-Well 96 Plate D.0 11 May 2020 • Updated the list of acceptable sample ty pes and added specimen storage conditions. • Remov ed catalog numbers f or combo kit components. • Updated materials listed in “Required materials not supplied” on page 11. • Updated the automated RNA extraction procedure with new plastics, new instrument programs, and rev ised wash and plate handling steps. • Updated the manual RNA extraction procedure with an optional ethanol v olume f or 200‑μL sample input v olumes, and an option to use the MagMAX™ Viral/Pathogen II Nucleic Acid Isolation Kit f or 400‑μL sample input v olumes. • Updated the real-time RT-PCR preparation procedure with new instructions f or 384‑well plates, clarif ied guidelines f or negativ e controls, and optional plates without barcodes. • Added procedures f or the QuantStudio™ 7 Flex Real-Time PCR Instrument (384-well block) and the QuantStudio™ 5 Real‑Time PCR Instrument (384-well block). • Added instrument f irmware requirements and remov ed calibration plates f or the QuantStudio™ 5 Real‑Time PCR Instrument. • Added Applied Biosystems™ COVID‑19 Interpretiv e Sof tware v 2.2. • Updated control requirements in interpretation of results, based on addition of 384-well plates. C.0 20 April 2020 • Remov ed 100-reaction kit. • Added a catalog number f or the KingFisher™ Deep-Well 96 Plate. • Updated the catalog number f or the Compact Digital Microplate Shaker. • Added catalog number f or the MagMAX™ Viral/Pathogen Nucleic Acid Isolation Kit and remov ed catalog numbers f or indiv idual components of the kit. • Added the MagMAX™ Viral/Pathogen II Nucleic Acid Isolation Kit. • Added an option to extract RNA with 200 µL of sample. • Added Applied Biosystems™ 7500 Real‑Time PCR Instrument and Applied Biosystems™ QuantStudio™ 5 Real‑Time PCR Instruments. • Added Applied Biosystems™ COVID‑19 Interpretiv e Sof tware v 1.2 and Applied Biosystems™ COVID‑19 Interpretiv e Sof tware v 2.0. • Remov ed Applied Biosy stems™ COVID‑19 Interpretiv e Sof tware v 1.0 and Applied Biosystems™ and COVID‑19 Interpretiv e Sof tware v 1.1. • Added specif ic instructions to v ortex and centrif uge the reaction plate f or RT-PCR (“Prepare the RT‑PCR reactions (400‑µL sample input, 96‑well reaction plate, COVID-19 assay only )” on page 40 and “Prepare the RT‑PCR reactions (200‑µL sample input, 96‑well reaction plate, COVID-19 assay only )” on page 36). • Specif ied that retesting must be done with the original sample (“Interpretation of the results” on page 106). • Reorganized the content to perf orm RT-PCR based on the real-time PCR instrument. • Added “Interf ering substances” on page 115. • Added inf ormation to customer and technical support (page 124). Rev ision Date Description B.0 24 March 2020 • Added MagMAX™ Viral/Pathogen Nucleic Acid Isolation Kit components f or 1,000 preparations to Required Materials. • Added manual RNA extraction protocol and required materials f or the manual RNA extraction protocol. • Added Applied Biosy stems™ 7500 Fast Real‑Time PCR Instrument. • Remov ed storage options f or RNA af ter extraction. • Updated guidelines f or RT-PCR to run the plate immediately af ter preparation and to keep the plate on ice until it is loaded into the real-time PCR instrument. • When setting up the RT-PCR reaction, added instructions to mix by pipetting up and down 10 times and seal and centrif uge the reaction plate. • Added COVID‑19 Interpretiv e Sof tware v 1.1 (compatible with Applied Biosystems™ 7500 Fast Real‑Time PCR Instrument and Applied Biosystems™ 7500 Fast Dx Real‑Time PCR Instrument). • Added that the run f ile must be opened, analy zed, and sav ed in the instrument sof tware bef ore it is opened in COVID‑19 Interpretiv e Sof tware. • For TaqPath™ COVID-19 RT-PCR Kit, 1,000 reactions (Cat. No. A47817), changed MS2 Phage Control f rom 20 tubes × 500 µL to 10 tubes × 1,000 µL. • Updated instructions to obtain the COVID‑19 Interpretiv e Sof tware. • Changed Limit of Detection and Clinical Ev aluation data to 1 decimal place. A.0 15 March 2020 New document. TRADEMARKS: All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Nasacort is a trademark of AVENTISUB LLC. Dymista is a trademark of Meda Pharmaceuticals Inc. NeilMed and Nasogel are trademarks of NeilMed Products, Inc.
Load more

Recommended publications
  • Applied Biosystems 3730 and 3730Xl DNA Analyzers
    SPECIFICATION SHEET 3730 and 3730xl DNA Analyzers Applied Biosystems 3730 and 3730xl DNA Analyzers Introduction Applied Biosystems 3730 & 3730xl DNA Analyzers were developed to meet the growing needs of institutions ranging from core and research labs in academia, government, and medicine to biotechnology, pharmaceuticals, and genome centers. These high-throughput instruments couple advances in automation and optics with proprietary Applied Biosystems reagents and software to support a diverse range Key Features Key Benefits of genetic analysis projects. By • Dual-side capillary illumination • Highest-quality DNA sequencing data dramatically improving data quality, at lowest cost • Backside-thinned CCD significantly reducing total cost per – POP-7™ Polymer separation matrix sample, and enabling more runs per • Integrated auto-sampler and sample increases read length and reduces day, 3730/3730xl DNA Analyzers make plate stacker run time it quicker and easier for investigators • Onboard piercing station to get meaningful results in evolving – Multiple run modules provide options genomic applications. Whether your • Internal barcode reader for targeted length of read lab is involved in de novo sequencing, • Onboard polymer for up to 100 runs – High optical sensitivity reduces DNA resequencing, microsatellite-based and reagent consumption fragment analysis, or SNP genotyping, • Automated basecalling and quality 3730/3730xl DNA Analyzers are the value assignment – In-capillary detection consumes ideal platform for better, faster, cheaper •
    [Show full text]
  • Automated DNA Sequencing
    Automated DNA Sequencing Chemistry Guide ©Copyright 1998, The Perkin-Elmer Corporation This product is for research purposes only. ABI PRISM, MicroAmp, and Perkin-Elmer are registered trademarks of The Perkin-Elmer Corporation. ABI, ABI PRISM, Applied Biosystems, BigDye, CATALYST, PE, PE Applied Biosystems, POP, POP-4, POP-6, and Primer Express are trademarks of The Perkin-Elmer Corporation. AmpliTaq, AmpliTaq Gold, and GeneAmp are registered trademarks of Roche Molecular Systems, Inc. Centricon is a registered trademark of W. R. Grace and Co. Centri-Sep is a trademark of Princeton Separations, Inc. Long Ranger is a trademark of The FMC Corporation. Macintosh and Power Macintosh are registered trademarks of Apple Computer, Inc. pGEM is a registered trademark of Promega Corporation. Contents 1 Introduction. 1-1 New DNA Sequencing Chemistry Guide . 1-1 Introduction to Automated DNA Sequencing . 1-2 ABI PRISM Sequencing Chemistries . 1-5 PE Applied Biosystems DNA Sequencing Instruments . 1-7 Data Collection and Analysis Settings . 1-12 2 ABI PRISM DNA Sequencing Chemistries . 2-1 Overview . 2-1 Dye Terminator Cycle Sequencing Kits . 2-2 Dye Primer Cycle Sequencing Kits . 2-8 Dye Spectra . 2-12 Chemistry/Instrument/Filter Set Compatibilities . 2-13 Dye/Base Relationships for Sequencing Chemistries . 2-14 Choosing a Sequencing Chemistry. 2-15 3 Performing DNA Sequencing Reactions . 3-1 Overview . 3-1 DNA Template Preparation . 3-2 Sequencing PCR Templates . 3-10 DNA Template Quality. 3-15 DNA Template Quantity. 3-17 Primer Design and Quantitation . 3-18 Reagent and Equipment Considerations. 3-20 Preparing Cycle Sequencing Reactions . 3-21 Cycle Sequencing . 3-27 Preparing Extension Products for Electrophoresis .
    [Show full text]
  • Document Title: Development and Evaluation of a Whole Genome Amplification Method for Accurate Multiplex STR Genotyping of Compromised Forensic Casework Samples
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Development and Evaluation of a Whole Genome Amplification Method for Accurate Multiplex STR Genotyping of Compromised Forensic Casework Samples Author: Tracey Dawson Cruz, Ph.D. Document No.: 227501 Date Received: July 2009 Award Number: 2005-DA-BX-K002 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. FINAL TECHNICAL REPORT Development and Evaluation of a Whole Genome Amplification Method for Accurate Multiplex STR Genotyping of Compromised Forensic Casework Samples NIJ Award #: 2005-DA-BX-K002 Author: Tracey Dawson Cruz 1 This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S.
    [Show full text]
  • List of SARS-Cov-2 Diagnostic Test Kits and Equipments Eligible For
    Version 33 2021-09-24 List of SARS-CoV-2 Diagnostic test kits and equipments eligible for procurement according to Board Decision on Additional Support for Country Responses to COVID-19 (GF/B42/EDP11) The following emergency procedures established by WHO and the Regulatory Authorities of the Founding Members of the GHTF have been identified by the QA Team and will be used to determine eligibility for procurement of COVID-19 diagnostics. The product, to be considered as eligible for procurement with GF resources, shall be listed in one of the below mentioned lists: - WHO Prequalification decisions made as per the Emergency Use Listing (EUL) procedure opened to candidate in vitro diagnostics (IVDs) to detect SARS-CoV-2; - The United States Food and Drug Administration’s (USFDA) general recommendations and procedures applicable to the authorization of the emergency use of certain medical products under sections 564, 564A, and 564B of the Federal Food, Drug, and Cosmetic Act; - The decisions taken based on the Canada’s Minister of Health interim order (IO) to expedite the review of these medical devices, including test kits used to diagnose COVID-19; - The COVID-19 diagnostic tests approved by the Therapeutic Goods Administration (TGA) for inclusion on the Australian Register of Therapeutic Goods (ARTG) on the basis of the Expedited TGA assessment - The COVID-19 diagnostic tests approved by the Ministry of Health, Labour and Welfare after March 2020 with prior scientific review by the PMDA - The COVID-19 diagnostic tests listed on the French
    [Show full text]
  • Rutgers Clinical Genomics Laboratory Taqpath SARS-Cov-2 Assay EUA Summary
    Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay EUA Summary ACCELERATED EMERGENCY USE AUTHORIZATION (EUA) SUMMARY SARS-CoV-2 ASSAY (Rutgers Clinical Genomics Laboratory) For in vitro diagnostic use Rx only For use under Emergency Use Authorization (EUA) Only (The Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay will be performed in the Rutgers Clinical Genomics Laboratory, a Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a certified high-complexity laboratory, per the Instructions for Use that were reviewed by the FDA under this EUA). INTENDED USE The Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay is a real-time reverse transcription polymerase chain reaction (rRT-PCR) test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in oropharyngeal (throat) swab, nasopharyngeal swab, anterior nasal swab, mid-turbinate nasal swab, and bronchoalveolar lavage (BAL) fluid from individuals suspected of COVID-19 by their healthcare provider. This test is also for use with saliva specimens that are self-collected at home or in a healthcare setting by individuals using the Spectrum Solutions LLC SDNA-1000 Saliva Collection Device when determined to be appropriate by a healthcare provider. Testing is limited to Rutgers Clinical Genomics Laboratory (RCGL) at RUCDR Infinite Biologics – Rutgers University, Piscataway, NJ, that is a Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a certified high-complexity laboratory. Results are for the detection and identification of SARS-CoV-2 RNA. The SARS- CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection.
    [Show full text]
  • DNA Fragment Analysis by Capillary Electrophoresis User Guide
    USER GUIDE DNA Fragment Analysis by Capillary Electrophoresis Publication Number 4474504 Revision B For Research Use Only. Not intended for use in diagnostic procedures. For Research Use Only. Not intended for use in diagnostic procedures. The information in this guide is subject to change without notice. DISCLAIMER LIFE TECHNOLOGIES CORPORATION AND/OR ITS AFFILIATE(S) DISCLAIM ALL WARRANTIES WITH RESPECT TO THIS DOCUMENT, EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO THOSE OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. TO THE EXTENT ALLOWED BY LAW, IN NO EVENT SHALL LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE OR ON ANY OTHER BASIS FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO THE USE THEREOF. TRADEMARKS All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. AmpErase, AmpliTaq, AmpliTaq Gold, and TaqMan are registered trademarks of Roche Molecular Systems, Inc. AFLP is a registered trademark of Keygene N.V. Millipore is a registered trademark of Merck KGaA. © 2014 Thermo Fisher Scientific Inc. All rights reserved. Contents About This Guide . 13 Revision history . 13 Purpose . 13 Prerequisites . 13 Structure of this guide . 14 ■ CHAPTER 1 Introduction to Fragment Analysis . 15 Fragment analysis versus sequencing…what is the difference? . 15 Fragment analysis . 15 Sequencing . 16 What can I do with fragment analysis? . 16 Types of applications . 16 Applications described in this guide . 17 What is capillary electrophoresis? . 18 Fragment analysis workflow . 19 ■ CHAPTER 2 Experimental Design .
    [Show full text]
  • Supporting Information Supplementary Methods
    Supporting Information Supplementary methods This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Caly L, Druce J, Roberts J, et al. Isolation and rapid sharing of the 2019 novel coronavirus (SAR-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med J Aust 2020; doi: 10.5694/mja2.50569. Supplementary methods 1.1 Generation of SARS-CoV-2 cDNA 200μL aliquots from swab (nasopharyngeal in VTM), sputum, urine, faeces and serum samples were subjected to RNA extraction using the QIAamp 96 Virus QIAcube HT Kit (Qiagen, Hilden, Germany) and eluted in 60μL. Reverse transcription was performed using the BioLine SensiFAST cDNA kit (Bioline, London, United Kingdom), total reaction mixture (20μL), containing 10μL RNA extract, 4μL 5x TransAmp buffer, 1μL reverse transcriptase and 5μL nuclease-free water. The reactions were incubated at 25°C for 10 min, 42°C for 15 min and 85°C for 5 min. 1.2 Nested SARS-CoV-2 RT-PCR and Sanger sequencing A PCR mixture containing 2μL cDNA, 1.6 μl 25mM MgCl2, 4μL 10x Qiagen Taq Buffer, 0.4μL 20mM dNTPs, 0.3μL Taq polymerase (Qiagen, Hilden, Germany) and 2μL of 10 μM primer pools as described2. Briefly, first round included the forward (5'-GGKTGGGAYTAYCCKAARTG-3') and reverse (5'-GGKTGGGAYTAYCCKAARTG-3') primers. Cycling conditions were 94°C for 10min, followed by 30 cycles of 94°C for 30s, 48°C for 30s and 72°C for 40s, with a final extension of 72°C for 10 min.
    [Show full text]
  • Applied Biosystems 3130 and 3130Xl Genetic Analyzers
    System Profile Applied Biosystems 3130 and 3130xl Genetic Analyzers. System Profile Applied Biosystems 3130 and 3130xl Genetic Analyzers Table of Contents A Powerful Blend of Flexibility and Performance 1 Ease-of-Use 1 Key Features 2 Capillary Electrophoresis 2 Automated Polymer Delivery System 2 Enhanced Thermal Control 2 High-Perfomance Capillaries and Electro-osmotic Flow Suppression (EOF) Polymers 2 Detection Method Designed for Sensitivity 3 Spectral Array Detection 3 Application Flexibility 4 Complete System Optimized for Multiple Applications 4 One Polymer, One Array, Maximum Performance 4 System Software Suite 5 Results 6 Summary 9 References 10 www.appliedbiosystems.com 16-capillary 3130xl Genetic Analyzer: High-performance workhorse. With 16-capillary throughput and advanced automation capabilities, the 3130xl system is flexible enough to meet the throughput needs of the busiest core facility or research group. The streamlined set-up and 24-hour unattended operation make it an ideal choice for low or medium throughput laboratories. Ease-of-Use Complete automation. At every scale, Applied Biosystems genetic analyzers are known for their advanced automation and “hands-free” operation. The Automated Polymer Delivery System A Powerful Blend of Flexibility and Performance eliminates manual washing and filling of polymer syringes, Applied Biosystems has a long tradition of providing significantly reducing the time required for instrument set- excellence in life science instruments, reagents, and software. up and maintenance. All steps are automated, including This tradition of pioneering and innovation in the field polymer loading, sample injection, separation and detection, of genetic analysis continues with the introduction of and data analysis. After placing plates on the autosampler Applied Biosystems next-generation systems, the 3130 and importing sample information, just select the “Start and 3130xl Genetic Analyzers.
    [Show full text]
  • Polymerase Chain Reaction Assay for Detection and Identity of Extraneous Chicken Anemia Virus (CAV)
    VIRPRO0118.05 Page 1 of 13 United States Department of Agriculture Center for Veterinary Biologics Testing Protocol Polymerase Chain Reaction Assay for Detection and Identity of Extraneous Chicken Anemia Virus (CAV) Date: September 25, 2014 Number: VIRPRO0118.05 Supersedes: VIRPRO0118.04, June 28, 2011 Contact: Sandra K. Conrad, (515) 337-7200 Danielle M. Koski Approvals: /s/Geetha B. Srinivas Date: 13Nov14 Geetha B. Srinivas, Section Leader Virology /s/Rebecca L.W. Hyde Date: 18Nov14 Rebecca L.W. Hyde, Section Leader Quality Management Center for Veterinary Biologics United States Department of Agriculture Animal and Plant Health Inspection Service P. O. Box 844 Ames, IA 50010 Mention of trademark or proprietary product does not constitute a guarantee or warranty of the product by USDA and does not imply its approval to the exclusion of other products that may be suitable. UNCONTROLLED COPY Center for Veterinary Biologics VIRPRO0118.05 Testing Protocol Page 2 of 13 Polymerase Chain Reaction Assay for Detection and Identity of Extraneous Chicken Anemia Virus (CAV) Table of Contents 1. Introduction 2. Materials 2.1 Equipment/instrumentation 2.2 Reagents/supplies 3. Preparation for the Test 3.1 Personnel qualifications/training 3.2 Preparation of equipment/instrumentation 3.3 Preparation of reagents/control procedures 3.4 Storage of the sample 4. Performance of the Test 4.1 DNA extraction 4.2 Amplification of CAV DNA 4.3 Analysis of amplified CAV DNA 5. Interpretation of the Test Results 6. Report of Test Results 7. Summary of Revisions UNCONTROLLED COPY Center for Veterinary Biologics VIRPRO0118.05 Testing Protocol Page 3 of 13 Polymerase Chain Reaction Assay for Detection and Identity of Extraneous Chicken Anemia Virus (CAV) 1.
    [Show full text]
  • Brochure: Biotech Essentials
    High-performance, flexible and reliable products that will set you up for success thermofisher.com/biotechessentials Techniques like cell growth, modification and analysis, sample preparation, PCR, qPCR, sequencing, electrophoresis and western blotting are the building blocks of your projects. Getting these fundamentals right first-time is critical to you moving quickly and efficiently towards your end goal. In order to do this, you need a partner who can supply all the right products and services. They need to be reliable, flexible, scalable and save you time so that you can minimise development and product costs, reduce risk, and reach your next milestone faster. We have a whole range of solutions dedicated to serving these needs ranging from off-the-shelf and customisable reagents and instruments to outsourcing services and manufacturing solutions. Take a look through this brochure to find out more. We’ll work with you every step of the way to ensure you’re set for success. Cell growth, scale-up and modification 4 Cellular analysis 6 Cellular analysis screening 8 Sample preparation 10 Synthetic biology 12 PCR 14 Electrophoresis 16 RNA extraction and cDNA synthesis for qPCR 17 Real-time PCR 18 Sanger and next-generation sequencing 20 Protein analysis 22 Outsourcing services 25 Custom manufacturing and commercial supply 26 Opening a new lab or relocating? 28 3 Cell Growth, Scale-up and Modification Whether you are culturing or modifying your cells, our range of Gibco™, Thermo Scientific™ Nunc™ and Invitrogen™ products will deliver the quality, consistency and performance you need at every step of your journey from discovery to commercialisation.
    [Show full text]
  • Relative Quantification Getting Started Guide for the Applied Biosystems 7300/7500/7500 Fast Real-Time PCR System RQ Experiment Workflow
    Getting Started Guide Relative Quantification Introduction and Example Applied Biosystems 7300/7500/7500 Fast RQ Experiment Real-Time PCR System Designing an RQ Experiment Performing Primer Extended on mRNA 5′ 3′ 5′ cDNA Reverse Primer Oligo d(T) or random hexamer Reverse Synthesis of 1st cDNA strand 3′ 5′ cDNA Transcription Generating Data from STANDARD RQ Plates - Standard Generating Data from FAST RQ Plates - Fast System Generating Data in an RQ Study © Copyright 2004, Applied Biosystems. All rights reserved. For Research Use Only. Not for use in diagnostic procedures. Authorized Thermal Cycler This instrument is an Authorized Thermal Cycler. Its purchase price includes the up-front fee component of a license under United States Patent Nos. 4,683,195, 4,683,202 and 4,965,188, owned by Roche Molecular Systems, Inc., and under corresponding claims in patents outside the United States, owned by F. Hoffmann-La Roche Ltd, covering the Polymerase Chain Reaction ("PCR") process to practice the PCR process for internal research and development using this instrument. The running royalty component of that license may be purchased from Applied Biosystems or obtained by purchasing Authorized Reagents. This instrument is also an Authorized Thermal Cycler for use with applications licenses available from Applied Biosystems. Its use with Authorized Reagents also provides a limited PCR license in accordance with the label rights accompanying such reagents. Purchase of this product does not itself convey to the purchaser a complete license or right to perform the PCR process. Further information on purchasing licenses to practice the PCR process may be obtained by contacting the Director of Licensing at Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404.
    [Show full text]
  • Real-Time Fluorescent RT-PCR Kit for Detecting SARS-Cov-2
    Real-Time Fluorescent RT-PCR Kit for Detecting SARS-CoV-2 For Emergency Use Only Instructions for Use (50 reactions/kit) For in vitro Diagnostic (IVD) Use Rx Only Labeling Revised: January XX, 2021 BGI Genomics Co. Ltd. (“BGI”) Building No. 7, BGI Park No. 21 Hongan 3rd Street Yantian District, Shenzhen, 518083 China, (+86) 400-706-6615 1 Table of Contents Table of Contents ................................................................................................................... 2 Intended Use ......................................................................................................................... 3 Summary and Explanation ....................................................................................................... 4 Principles and Procedure ......................................................................................................... 5 Materials Provided ................................................................................................................. 6 Materials and Equipment Required But Not Provided .................................................................. 7 Warnings and Precautions........................................................................................................ 8 Reagent Storage, Handling, and Stability ..................................................................................11 Specimen Collection, Storage, and Transfer ..............................................................................12 Laboratory Procedures ...........................................................................................................13
    [Show full text]